An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 4, 2015, Pages 399-405

  Mcdonald, Cameron J ^a   Kalisch Ellett, Lisa M ^a   Barratt, John D ^a   Caughey, Gillian E ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Adverse event; Dabigatran; Haemorrhage; Inappropriate prescribing; Pharmacoepidemiology

Indexed keywords

AMIODARONE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYCLOSPORIN; DABIGATRAN; DRONEDARONE; GLYCOPROTEIN; HEPARIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MACROLIDE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; THROMBIN INHIBITOR; VERAPAMIL; WARFARIN; ANTITHROMBIN;

ADVERSE OUTCOME; AGED; ARTICLE; AUSTRALIA; BLEEDING; CANADA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG INTERACTION; DRUG SURVEILLANCE PROGRAM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; NERVOUS SYSTEM; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK FACTOR; UNITED STATES; COMPARATIVE STUDY; FACTUAL DATABASE; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTITHROMBINS; AUSTRALIA; CANADA; DABIGATRAN; DATABASES, FACTUAL; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; UNITED STATES;

EID: 84925934946     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3648     Document Type: Article

References (22)

1. Adam SS, McDuffie JR, Ortel TL, Williams JJW. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012; 157(11): 796-807.
2. Sipahi I, Celik S, Tozun N. A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med 2013; 174(1): 150-151.
3. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial. Circulation 2012; 125(5): 669-676.
4. Legrand M, Mateo J, Aribaud A. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171(14): 1285-1286.
5. Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 2012; 125(1): 159-164.
6. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology (5th edn). Wiley-Blackwell: West Sussex, UK, 2012.
7. Australian Therapeutic Goods Administration. Database of adverse event notifications (DAEN). Secondary Database of Adverse Event Notifications (DAEN) 2013. http://www.tga.gov.au/safety/daen.htm [25 June 2013].
8. Health Canada. Canada vigilance adverse reaction online database. Secondary Canada Vigilance Adverse Reaction Online Database 2013. http://www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php [1 July 2013].
9. U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS). Secondary FDA Adverse Event Reporting System (FAERS) 2013. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm [25 June 2013].
10. Therapeutic Guidelines Limited. Therapeutic guidelines: cardiovascular. Version 6. 2012 http://www.tg.org.au/ [25 July 2013].
11. Australian Medicines Handbook. Australian Medicines Handbook Pty. Ltd.: Adelaide, Australia, 2013.
12. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10(6): 483-486.
13. Egberts ACG, Meyboom RHB, Van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002; 25(6): 453-458.
14. Connolly S, Ezekowitz M, Phil D, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-1151.
15. Dans A, Connolly S, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127(5): 634-640.
16. NPS Medicine Wise. Interactions with dabigatran, rivaroxaban and apixaban. Secondary Interactions with dabigatran, rivaroxaban and apixaban. 2013. http://www.nps.org.au/medicines/heart-blood-and-blood-vessels/anti-clotting-medicines/for-individuals/anticoagulant-medicines/for-health-professionals/decision-tools/newer-anticoagulant-drug-interactions [10 September 2013].
17. Shorr R, Ray W, Daugherty J, Griffin M. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for haemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153(14): 1665-1670.
18. Paton C, Ferrier N. SSRIs and gastrointestinal bleeding: gastroprotection may be justified in some patients. BMJ 2005; 331(7516): 529-530.
19. Boehringer Ingelheim Pharmaceuticals. RELY-ABLE trial emergency information. Secondary RELY-ABLE Trial Emergency Information 2013. http://www.rely-able-trial.com/Rely2Web/index.jsp [2 November 2013].
20. Rawlins MD. A population approach to the rational use of therapeutic interventions. Clin Ther 2013; 35(10): 1634-1638.
21. Shah B, Hajjar E. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med 2012; 28(2): 173-186.
22. Shah BR, Hux JE, Laupacis A, Zinman B, Booth GL. Use of vascular risk-modifying medications for diabetic patients differs between physician specialties. Diabet Med 2006; 23(10): 1117-1123.